Curcumin and Its Derivatives as Theranostic Agents in Alzheimer's Disease: The Implication of Nanotechnology

被引:69
|
作者
Shabbir, Umair [1 ]
Rubab, Momna [1 ]
Tyagi, Akanksha [1 ]
Oh, Deog-Hwan [1 ]
机构
[1] Kangwon Natl Univ, Dept Food Sci & Biotechnol, Coll Agr & Life Sci, Chunchon 200701, South Korea
关键词
neurodegenerative disorder; curcumin; nanoparticles; diagnosis; therapeutic; BLOOD-BRAIN-BARRIER; AMYLOID-BETA AGGREGATION; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; TAU AGGREGATION; NANOPARTICLES; PLAQUES; PREVENTION; DIAGNOSIS; PATHOLOGY;
D O I
10.3390/ijms22010196
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Curcumin is a polyphenolic natural compound with diverse and attractive biological properties, which may prevent or ameliorate pathological processes underlying age-related cognitive decline, Alzheimer's disease (AD), dementia, or mode disorders. AD is a chronic neurodegenerative disorder that is known as one of the rapidly growing diseases, especially in the elderly population. Moreover, being the eminent cause of dementia, posing problems for families, societies as well a severe burden on the economy. There are no effective drugs to cure AD. Although curcumin and its derivatives have shown properties that can be considered useful in inhibiting the hallmarks of AD, however, they have low bioavailability. Furthermore, to combat diagnostic and therapeutic limitations, various nanoformulations have also been recognized as theranostic agents that can also enhance the pharmacokinetic properties of curcumin and other bioactive compounds. Nanocarriers have shown beneficial properties to deliver curcumin and other nutritional compounds against the blood-brain barrier to efficiently distribute them in the brain. This review spotlights the role and effectiveness of curcumin and its derivatives in AD. Besides, the gut metabolism of curcumin and the effects of nanoparticles and their possible activity as diagnostic and therapeutic agents in AD also discussed.
引用
收藏
页码:1 / 23
页数:23
相关论文
共 50 条
  • [1] Curcumin derivatives as a potential theranostic agents for Alzheimer's disease
    Bednarikova, Z.
    Orteca, G.
    Ferrari, E.
    Asti, M.
    Menziani, M. C.
    Gazova, Z.
    EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2017, 46 : S237 - S237
  • [2] Curcumin–pluronic nanoparticles: A theranostic nanoformulation for alzheimer’s disease
    Singh A.
    Mahajan S.D.
    Kutscher H.L.
    Kim S.
    Prasad P.N.
    Critical Reviews in Biomedical Engineering, 2020, 48 (03) : 153 - 168
  • [3] Bifunctional compounds as novel theranostic agents for Alzheimer's disease
    Mirica, Liviu
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [4] Curcumin in Health and Diseases: Alzheimer's Disease and Curcumin Analogues, Derivatives, and Hybrids
    Chainoglou, Eirini
    Hadjipavlou-Litina, Dimitra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (06)
  • [5] Curcumin/melatonin hybrids as neuroprotective agents for Alzheimer's disease
    Saathoff, John
    Liu, Kai
    Chojnacki, Jeremy
    Zhang, Shijun
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [6] Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
    Ahmad, Javed
    Akhter, Sohail
    Rizwanullah, Md.
    Khan, Mohammad Ahmed
    Pigeon, Lucie
    Addo, Richard T.
    Greig, Nigel H.
    Midoux, Patrick
    Pichon, Chantal
    Kamal, Mohammad Amjad
    CURRENT ALZHEIMER RESEARCH, 2017, 14 (11) : 1164 - 1181
  • [7] Alzheimer's Disease: Pathophysiology and Applications of Magnetic Nanoparticles as MRI Theranostic Agents
    Amiri, Houshang
    Saeidi, Kolsoum
    Borhani, Parvin
    Manafirad, Arash
    Ghavami, Mahdi
    Zerbi, Valerio
    ACS CHEMICAL NEUROSCIENCE, 2013, 4 (11): : 1417 - 1429
  • [8] Bifunctional chemical agents as theranostic tools for Ab aggregation in Alzheimer's disease
    Mirica, Liviu M.
    Sharma, Anuj K.
    Schultz, Jason
    Prior, John
    Azanov, Philip
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [9] Nanotechnology in Alzheimer's disease
    不详
    MEDICINA-BUENOS AIRES, 2015, 75 (04) : 269 - 269
  • [10] Memantine Derivatives as Multitarget Agents in Alzheimer's Disease
    Marotta, Giambattista
    Basagni, Filippo
    Rosini, Michela
    Minarini, Anna
    MOLECULES, 2020, 25 (17):